This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ amidopyrine,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Analgesic and Antipyretic Effects: Amidopyrine was traditionally used to relieve pain and reduce fever, similar to other nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin or ibuprofen. It has both analgesic (pain-relieving) and antipyretic (fever-reducing) properties.

  2. Agranulocytosis: The most serious adverse effect associated with amidopyrine use is agranulocytosis, a condition characterized by a severe reduction in the number of granulocytes (a type of white blood cell) in the bloodstream. Agranulocytosis can increase the risk of severe infections and may be life-threatening if not promptly recognized and treated.

  3. Risk of Blood Disorders: In addition to agranulocytosis, amidopyrine use has been associated with other blood disorders, including leukopenia (reduced white blood cell count), thrombocytopenia (reduced platelet count), and aplastic anemia (bone marrow failure). These conditions can lead to bleeding, bruising, and increased susceptibility to infections.

  4. Hypersensitivity Reactions: Amidopyrine can cause hypersensitivity reactions, including allergic reactions and skin rashes. In some cases, severe hypersensitivity reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis may occur, which are serious and potentially life-threatening conditions characterized by widespread skin blistering and mucosal involvement.

  5. Renal and Hepatic Toxicity: Long-term use of amidopyrine may lead to renal (kidney) and hepatic (liver) toxicity, particularly in individuals with pre-existing kidney or liver conditions. Patients with impaired kidney or liver function should use amidopyrine with caution and under the guidance of a healthcare professional.

  6. Withdrawal of Amidopyrine: Due to the significant risk of agranulocytosis and other serious adverse effects associated with amidopyrine use, many countries have withdrawn it from the market or restricted its use. Safer alternatives for pain relief and fever reduction are now available and widely used, reducing the need for amidopyrine.

;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of amidopyrine,(prescription) On Probiotics

Rank Probiotic Impact
species Anaerobutyricum hallii Reduces
species Christensenella minuta Reduces
species Lactococcus cremoris Reduces

Bacteria Impacted by amidopyrine,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Ruminococcus genus Decreases
0 1 Coprococcus genus Decreases
0 1 Subdoligranulum genus Decreases
0 1 Wansuia genus Decreases
0 1 Vescimonas genus Decreases
0 1 Christensenella genus Decreases
0 1 Komagataeibacter genus Decreases
0 1 Butyrivibrio genus Decreases
0 1 Dorea genus Decreases
0 1 Maliibacterium genus Decreases
0 1 Mageeibacillus genus Decreases
0 1 Wujia genus Decreases
0 1 Eubacterium genus Decreases
0 1 Anaerobutyricum genus Decreases
0 1 Catenibacterium genus Decreases
0 1 Oscillibacter genus Decreases
0 1 Treponema genus Decreases
0 1 Massilistercora genus Decreases
0 1 Novisyntrophococcus genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Ligilactobacillus genus Decreases
0 1 Intestinimonas genus Decreases
1 0 Ruminococcus bromii species Decreases
1 0 Coprococcus comes species Decreases
0 1 Dorea longicatena species Decreases
0 1 Coprococcus catus species Decreases
0 1 Blautia obeum species Decreases
0 1 Dorea formicigenerans species Decreases
0 1 Wansuia hejianensis species Decreases
0 1 Anaerobutyricum hallii species Decreases
0 1 Blautia sp. SC05B48 species Decreases
0 1 Lacrimispora saccharolytica species Decreases
0 1 Subdoligranulum variabile species Decreases
0 1 Ligilactobacillus ruminis species Decreases
0 1 Komagataeibacter oboediens species Decreases
0 1 [Ruminococcus] lactaris species Decreases
0 1 [Ruminococcus] torques species Decreases
0 1 Eubacterium ventriosum species Decreases
0 1 Clostridium sp. M62/1 species Decreases
0 1 Coprococcus eutactus species Decreases
0 1 Lachnoanaerobaculum gingivalis species Decreases
0 1 Christensenella minuta species Decreases
0 1 Blautia liquoris species Decreases
0 1 Clostridium sp. SY8519 species Decreases
0 1 Butyrivibrio crossotus species Decreases
0 1 Coprococcus sp. ART55/1 species Decreases
0 1 Catenibacterium mitsuokai species Decreases
0 1 Faecalibacterium duncaniae species Decreases
0 1 Faecalitalea cylindroides species Decreases
0 1 Vescimonas fastidiosa species Decreases
0 1 Massilistercora timonensis species Decreases
0 1 Maliibacterium massiliense species Decreases
0 1 Eubacterium sp. MSJ-33 species Decreases
0 1 Treponema peruense species Decreases
0 1 Novisyntrophococcus fermenticellae species Decreases
0 1 Catenibacterium sp. co_0103 species Decreases
0 1 Qiania dongpingensis species Decreases
0 1 Faecalibacillus intestinalis species Decreases
0 1 Roseburia hominis species Decreases
0 1 [Clostridium] hylemonae species Decreases
0 1 Faecalibacterium sp. I2-3-92 species Decreases
0 1 Ruminococcus champanellensis species Decreases
0 1 Faecalibacterium sp. HTF-F species Decreases
0 1 Faecalibacterium sp. I4-1-79 species Decreases
0 1 Faecalibacterium sp. IP-3-29 species Decreases
0 1 Intestinibaculum porci species Decreases
0 1 Clostridium cadaveris species Decreases
0 1 Anaerostipes hadrus species Decreases
0 1 Pseudobutyrivibrio xylanivorans species Decreases
0 1 Lactococcus cremoris species Decreases
0 1 Vescimonas coprocola species Decreases
0 1 Lachnoclostridium phocaeense species Decreases
0 1 Marvinbryantia formatexigens species Decreases
0 1 Streptococcus suis species Decreases
0 1 Wujia chipingensis species Decreases
0 1 Lawsonibacter asaccharolyticus species Decreases
0 1 Longicatena caecimuris species Decreases
0 1 Faecalibacterium sp. I3-3-89 species Decreases
0 1 Ruminococcus bicirculans (ex Wegman et al. 2014) species Decreases
0 1 Mageeibacillus indolicus species Decreases
0 1 Faecalibacterium sp. IP-1-18 species Decreases
0 1 Solibaculum mannosilyticum species Decreases
0 1 Adlercreutzia equolifaciens species Decreases

Impact of amidopyrine,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
ADHD 0.5 0.7 -0.4
Age-Related Macular Degeneration and Glaucoma 0.3 0.3
Allergic Rhinitis (Hay Fever) 0.2 0.2 0
Allergies 1.2 1.3 -0.08
Allergy to milk products 0.9 0.2 3.5
Alopecia (Hair Loss) 0.2 0.1 1
Alzheimer's disease 1.3 1.1 0.18
Amyotrophic lateral sclerosis (ALS) Motor Neuron 0.6 0.6 0
Ankylosing spondylitis 0.3 0.6 -1
Anorexia Nervosa 0.5 0.6 -0.2
Asthma 0.1 0.1 0
Atherosclerosis 0.5 0.1 4
Atrial fibrillation 0.8 0.2 3
Autism 1.1 1 0.1
Bipolar Disorder 0.6 0.6 0
Brain Trauma 0.1 0.6 -5
Carcinoma 1.2 1.1 0.09
Celiac Disease 0.1 0.7 -6
Cerebral Palsy 0.1 0.5 -4
Chronic Fatigue Syndrome 1.2 2.1 -0.75
Chronic Kidney Disease 0.7 0.8 -0.14
Chronic Obstructive Pulmonary Disease (COPD) 0.3 0.3 0
Coagulation / Micro clot triggering bacteria 0.1 0.8 -7
Cognitive Function 0.7 0.2 2.5
Colorectal Cancer 0.8 0.2 3
Constipation 0.5 0.5
Coronary artery disease 0.8 0.6 0.33
COVID-19 1 3 -2
Crohn's Disease 1.4 1.6 -0.14
deep vein thrombosis 0.3 0.8 -1.67
Depression 1.3 1.9 -0.46
Eczema 0.1 -0.1
Endometriosis 0.4 0.6 -0.5
Epilepsy 0.3 0.1 2
erectile dysfunction 0.1 0.1
Fibromyalgia 0.1 0.5 -4
Functional constipation / chronic idiopathic constipation 0.9 1.1 -0.22
gallstone disease (gsd) 0.6 0.1 5
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0.5 -0.5
Generalized anxiety disorder 0.2 0.3 -0.5
Glioblastoma 0.1 0.1
Gout 0.5 0.2 1.5
Graves' disease 0.5 0.6 -0.2
Gulf War Syndrome 0.2 0.2
Halitosis 0.2 0.2
Hashimoto's thyroiditis 1.2 0.3 3
Heart Failure 0.9 1 -0.11
hemorrhagic stroke 0.2 0.2
High Histamine/low DAO 0.5 -0.5
Hyperlipidemia (High Blood Fats) 0.2 0.2
hypertension (High Blood Pressure 1.1 1.2 -0.09
Hypothyroidism 0.2 0.5 -1.5
Hypoxia 0.2 0.2
IgA nephropathy (IgAN) 0.6 0.3 1
Inflammatory Bowel Disease 0.6 2.2 -2.67
Insomnia 0.7 0.5 0.4
Intelligence 0.2 0.4 -1
Intracranial aneurysms 0.5 0.3 0.67
Irritable Bowel Syndrome 1.1 1 0.1
ischemic stroke 0.5 0.5
Juvenile idiopathic arthritis 0.1 -0.1
Liver Cirrhosis 1.4 1.2 0.17
Long COVID 0.9 2.6 -1.89
Low bone mineral density 0.5 -0.5
Lung Cancer 0.8 -0.8
Mast Cell Issues / mastitis 0.6 -0.6
ME/CFS with IBS 1.4 -1.4
ME/CFS without IBS 0.2 0.5 -1.5
Menopause 0.2 0.2
Metabolic Syndrome 1.6 1.8 -0.13
Mood Disorders 1.3 1.2 0.08
Multiple Sclerosis 0.6 1 -0.67
Multiple system atrophy (MSA) 0.1 0.5 -4
myasthenia gravis 0.1 -0.1
neuropathic pain 0.1 -0.1
Neuropathy (all types) 0.1 0.1
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.9 1.5 -0.67
Obesity 2.2 1.8 0.22
obsessive-compulsive disorder 1.2 0.6 1
Osteoarthritis 0.4 0.8 -1
Osteoporosis 0.5 0.3 0.67
Parkinson's Disease 1.8 1.4 0.29
Polycystic ovary syndrome 1.7 1.1 0.55
Postural orthostatic tachycardia syndrome 0.2 -0.2
primary biliary cholangitis 0.2 0.2
Primary sclerosing cholangitis 1.2 -1.2
Psoriasis 0.7 0.3 1.33
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 2 0.4 4
Rosacea 0.6 0.6
Schizophrenia 0.9 0.8 0.13
scoliosis 0.4 0.5 -0.25
sensorineural hearing loss 0.3 0.1 2
Sjögren syndrome 0.3 -0.3
Sleep Apnea 1 0.2 4
Slow gastric motility / Gastroparesis 0.6 0.6
Small Intestinal Bacterial Overgrowth (SIBO) 0.3 0.3
Stress / posttraumatic stress disorder 0.2 0.2 0
Systemic Lupus Erythematosus 0.3 0.6 -1
Tic Disorder 0.5 0.5 0
Tourette syndrome 0.1 0.1
Type 1 Diabetes 0.6 0.9 -0.5
Type 2 Diabetes 1.7 1.4 0.21
Ulcerative colitis 0.5 1.3 -1.6
Unhealthy Ageing 0.4 0.4 0
Vitiligo 0.6 0.4 0.5

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]